Bicycle Therapeutics’ (BCYC) Sell (D-) Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (d-) rating on shares of Bicycle Therapeutics (NASDAQ:BCYC) in a research note issued to investors on Tuesday morning,Weiss Ratings reports.

A number of other equities research analysts also recently issued reports on BCYC. Morgan Stanley reduced their price objective on shares of Bicycle Therapeutics from $17.00 to $13.00 and set an “equal weight” rating for the company in a research report on Tuesday, August 12th. JMP Securities cut their target price on Bicycle Therapeutics from $22.00 to $10.00 and set a “market outperform” rating on the stock in a research note on Tuesday, August 12th. Oppenheimer reaffirmed an “outperform” rating and set a $44.00 price target (down from $48.00) on shares of Bicycle Therapeutics in a research report on Monday, August 11th. Finally, Royal Bank Of Canada set a $27.00 price target on Bicycle Therapeutics and gave the stock an “outperform” rating in a report on Monday, August 11th. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $22.22.

Bicycle Therapeutics Trading Up 3.1%

Shares of Bicycle Therapeutics stock opened at $8.65 on Tuesday. The company has a market capitalization of $599.53 million, a P/E ratio of -2.46 and a beta of 1.47. The stock has a fifty day simple moving average of $7.48 and a 200 day simple moving average of $7.78. Bicycle Therapeutics has a 12-month low of $6.10 and a 12-month high of $27.70.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Friday, August 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.19). The firm had revenue of $2.90 million for the quarter, compared to analysts’ expectations of $9.43 million. Bicycle Therapeutics had a negative return on equity of 32.43% and a negative net margin of 1,257.00%. On average, analysts predict that Bicycle Therapeutics will post -3.06 EPS for the current year.

Insider Buying and Selling

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,231 shares of the stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $8.41, for a total transaction of $27,172.71. Following the completion of the transaction, the chief executive officer directly owned 475,310 shares of the company’s stock, valued at approximately $3,997,357.10. This represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 8,527 shares of company stock valued at $71,738 in the last quarter. 22.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in BCYC. The Manufacturers Life Insurance Company boosted its stake in Bicycle Therapeutics by 1.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 140,492 shares of the company’s stock worth $976,000 after purchasing an additional 2,243 shares during the period. Virtus Investment Advisers LLC lifted its holdings in shares of Bicycle Therapeutics by 32.6% in the second quarter. Virtus Investment Advisers LLC now owns 10,821 shares of the company’s stock worth $75,000 after buying an additional 2,659 shares in the last quarter. Tocqueville Asset Management L.P. lifted its holdings in shares of Bicycle Therapeutics by 24.5% in the first quarter. Tocqueville Asset Management L.P. now owns 18,300 shares of the company’s stock worth $155,000 after buying an additional 3,600 shares in the last quarter. Exchange Traded Concepts LLC boosted its position in shares of Bicycle Therapeutics by 90.3% in the first quarter. Exchange Traded Concepts LLC now owns 12,764 shares of the company’s stock valued at $108,000 after acquiring an additional 6,057 shares during the period. Finally, GAMMA Investing LLC grew its stake in Bicycle Therapeutics by 879.5% during the first quarter. GAMMA Investing LLC now owns 8,982 shares of the company’s stock valued at $76,000 after acquiring an additional 8,065 shares in the last quarter. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.